He expects to make a huge profit. I think it's hilarious how folks with a few thousand shares long or short question a bio focused hedge fund with hundreds of millions of dollars under management headed by one of the smartest guys in the business.
He's going to win... You can take that to the bank.
Well Bunch, I can certainly support that.
Pascoe needs to shut TFU about shareholder value until there is some and that's a fact.
I'd even say, he should address this problem in his next public remarks.
I voted yes, and your incessant whining about it won't change the outcome of today's vote.
The only path to real increased shareholder value is to insure the company can meet the objectives of moving Fispemifene into the clinic, being ready to advance RayVa should the current trial show good results and to continue to market Vitaros in countries it's not yet partnered. These objectives require capital the company does not have... Nobody in their right mind thinks a complete halt of operations would be beneficial. So STF,,,, U....
If I'm a liar and you do the opposite of any of my suggestions would you not lose? Just saying...
I think Bic is correct in one line of thought but still wrong on what it means.
I think it's more than possible that Neil Morton was led to Fispemifene with help. And I think it's true Sarissa is here for Fispemifene. I know my fellow Longs would point to the early success of Vitaros, and the potential of RayVa, but RayVa has been in APRI's pipeline for years along with Vitaros and no bio focused hedge fund ever cared.
I think the thought that this is Sarissa's show, and that it's all about Fispemifene is 100% correct.
The idea they need any type of special inside dealings at this point is silly as you correctly point out. They have huge voting power, the ability to take a board seat whenever, and they must approve any dilution that effects their % ownership of the company. In addition they are on standby to be offered the opportunity to buy more and you are right they could most likely buy Forendo outright too.
Long or Short, we are all betting on or against Sarissa... Period.
Simple beanereno, I did not say France would get APRI $6 million in royalty in 24 months. I was saying France would eventually get there, but we are halfway thru 2105 now so IMO there is no way by end of 2016. But we can haggle over where we think the ceiling is, my point is the same. Vitaros is on autopilot and the future is Fispemifene.
Nothing draws the attention of money, like money. Look at Ackman and Icahn as an example. Do you think either has any real interest in Herbalife? I'd say the joy is in poking each other.
It's clear to me that Sarissa is "cornering" Fispemifene and I think it's possible that someone else accumulates too, and the only reason I think that is because Sarissa is like a fog horn blarring on a company with such a tiny market cap.
I also don't think it's likely that APRI stands alone far into 2016. If RPRX gets a favorable outcome then there will be offers for APRI especially with their phase 2 basically completed by November.
Which brings me to my biggest question mark... Why does the company need 150 million shares authorized? You know Sarissa wants them to do that... My hunch is, it's a bluff for an eventual sell of the company, but I do not know for sure. It would basically put APRI in a position that says, no matter the consequences to the PPS we are in a position to take Fispemifene all the way on our own even though doing so would be madness. It's a bargaining chip, at least that's my hunch.
Time will tell... But in short, Vitaros is great for what it is, RayVa is a non factor, and everyone is positioning for ownership of Fispemifene.
Let's start with Vitaros. Vitaros will not be shuttered or pulled off the market, or any such nonsense, and APRI is not simply filling sold batches in exchange for the up fronts received or whatever Bic was trying to say in his drunken state.
Vitaros is awesome in the following sense. It no longer costs shareholders money. It adds real revenue everyday to the company, and it's going to grow to be about 7 to 10 million per year in revenue against zero costs in the next 24 months. In France Caverject does almost $40 million per year in sales. That's the stab yourself with a needle in your manhood drug. I expect Vitaros to take all of that market share and with a 15% royalty there is $6 million alone in France.
But Bic is right about where the company was. Without Fispemifene shareholders would be looking at Vitaros sales and realizing they were only going to get 7 to 10 million per year in revenue and the only thing in the pipeline was RayVa and the stock might have gone to unthinkable lows. But any thought that the company would turn it's back on Vitaros now is nonsense. It's free money!!! The partners order from the manufacturer, pay the manufacturer the wholesale and then pay APRI on the sold thru to patients. It's a dream come true, too bad it's only going to net back about 7 to 10 million per year but again, that's against zero costs going forward.
Now on to the top priority of the company Fispemifene. Its who this company is, and it's why Sarissa Capital is on the stock. Most retail investors in APRI still think this is a Vitaros story. They are wrong. The legitimate questions are as follows. The LowT market is huge and Fispemifene if approved will be worth $1 billion + IMO. The problem is getting to approval. APRI does not have the money, and perhaps not the talent to run the clinicals. They have the money for the upcoming phase 2 but what happens next? Does Sarissa step up with another private placement? more to come.
Fispemifene that actually has a generic competitor on the market?
No it does not. Just because there is a bio similar SERM for women the 2 are not the same.
No Urologist in the USA is going to go off label for such and risk exposure of liability of side effects against the recommendations of labeling by the FDA. PERIOD!!! THAT"S NEVER GOING TO HAPPEN!!! Or it would be happening today, and it's not.
Stolen? Get a grip... Or chase down Demaj, Cox and Martin and have them explain why Vitaros is not the next big thing...
The company actually drew a needed Ace on the river card getting Fispemifene. You can b,,, itch about how you were suckered years ago or be thankful.
Look if you expect them to somehow announce that Vitaros sales are awesome and they see a ramp up to $20 million per year in royalty coming than you are just lying to yourself. NEVER GONNA HAPPEN!!!
That said, Fispemifene is 100% APRI's in the US and they are following a multi track indication and once approved it is in a multi billion dollar space and will compete effectively for market. Or at a minimum, once they advance the clinical track the odds of a buyout at much higher prices could be a reality.
FISPEMIFENE!!! FISPEMIFENE!!! FISPEMIFENE!!!
That's who this company is now.
To move forward on multiple indications for Fispemifene now rather than wait shows where the company thinking really is. I like the idea of pursing LUTS on a parallel track now.
If you hold APRI stock on an expectation of revenue success from Vitaros,,,, SELL!!!!!
Vitaros will eventually generate a nice but modest revenue stream into the future but the only reason to own APRI is Fispemifene!!! Do you honestly think Sarissa Capital gives a @#$% about Vitaros? They don't. They are here for Fispemifene... PERIOD.
Agreed, and that would be perfectly fine with me. I'd be ok if they got back decent data and still said (no go) at this time. The only reason they were advancing RayVa anyway is because they had no other option after they dropped moving Femprox forward. They needed something for the future because Vitaros would not be enough.
Then Neil Morton brings in the in license of Fispemifene. Fispemifene is worth billions in future sales... It's why Sarissa Capital jumped in with both feet IMO. No Fispemifene, no Sarissa.
They should cut expenses by dropping RayVa now, and focus 100% on Fispemifene and the Vitaros room temperature device which would serve to directly impact sales in Europe.